Liana Moussatos - Latest News and breaking headlines - Benzinga

Liana Moussatos

Intercept Pharma Notches 2 Upgrades On Ocaliva Prospects

Intercept Pharma Notches 2 Upgrades On Ocaliva Prospects

Wedbush Finally Steps Off The Sidelines, Bumps BioMarin To Outperform

Wedbush Finally Steps Off The Sidelines, Bumps BioMarin To Outperform

Kala Pharma Has 2 Material Milestones Upcoming In Q4

Kala Pharma Has 2 Material Milestones Upcoming In Q4

Wedbush Finally Steps Off The Sidelines, Bumps BioMarin To Outperform

Wedbush Finally Steps Off The Sidelines, Bumps BioMarin To Outperform

Kala Pharma Has 2 Material Milestones Upcoming In Q4

Kala Pharma Has 2 Material Milestones Upcoming In Q4

Global Blood Therapeutics' Acquisition Value Could Be At Least $3 Billion

Global Blood Therapeutics' Acquisition Value Could Be At Least $3 Billion

Expect A Pair Of Drug Approvals From BioMarin In 2017; Stock Remains Pricey

Expect A Pair Of Drug Approvals From BioMarin In 2017; Stock Remains Pricey

Global Blood Therapeutics' Acquisition Value Could Be At Least $3 Billion

Global Blood Therapeutics' Acquisition Value Could Be At Least $3 Billion

Expect A Pair Of Drug Approvals From BioMarin In 2017; Stock Remains Pricey

Expect A Pair Of Drug Approvals From BioMarin In 2017; Stock Remains Pricey

Why miRagen Therapeutics Shares Could See 60% Upside By 2018

Why miRagen Therapeutics Shares Could See 60% Upside By 2018

Analysts Split On How To Read Intercept Switching Clinical Trial Endpoints

Analysts Split On How To Read Intercept Switching Clinical Trial Endpoints

Liana Moussatos Recent News

Your Guide To 2017's Emerging Pharmaceuticals Catalysts

Your Guide To 2017's Emerging Pharmaceuticals Catalysts

'Steady Growth' For Relypsa's Veltassa Launch

'Steady Growth' For Relypsa's Veltassa Launch

Every Biotech Catalyst Wedbush Is Watching In 2016

Every Biotech Catalyst Wedbush Is Watching In 2016

Wedbush Hikes Relypsa Target To $86 On Edge Of U.S. Veltassa Launch

Wedbush Hikes Relypsa Target To $86 On Edge Of U.S. Veltassa Launch

Wedbush Offers Probabilities For Upcoming Catalysts In Emerging Pharmas

Wedbush Offers Probabilities For Upcoming Catalysts In Emerging Pharmas

EXCLUSIVE: Relypsa Being Evaluated By 3-4 Potential Acquirers; Sanofi Seen As 'Natural Buyer'

EXCLUSIVE: Relypsa Being Evaluated By 3-4 Potential Acquirers; Sanofi Seen As 'Natural Buyer'

Wedbush See 470% Upside At Xoma

Wedbush See 470% Upside At Xoma

Wedbush Upbeat On Vitae Pharmaceuticals Despite Diabetes Results

Wedbush Upbeat On Vitae Pharmaceuticals Despite Diabetes Results

Wedbush Sees Bidding War For Receptos

Wedbush Sees Bidding War For Receptos

Analysts Positive On Intercept Pharmaceuticals After Earnings, Pipeline Update

Analysts Positive On Intercept Pharmaceuticals After Earnings, Pipeline Update

Wedbush Securities Believes Financing Further Extends Cash Runway For Intercept Pharmaceuticals

Wedbush Securities Believes Financing Further Extends Cash Runway For Intercept Pharmaceuticals

Wedbush Securities Believes SH Data Bodes Well For Pacira Pharmaceuticals

Wedbush Securities Believes SH Data Bodes Well For Pacira Pharmaceuticals

Wedbush Expects Cash Runway To Last Through Anticipated Catalysts In 2015 For XOMA

Wedbush Expects Cash Runway To Last Through Anticipated Catalysts In 2015 For XOMA

Will Intercept Pharma Outperform? These Analysts Think So

Will Intercept Pharma Outperform? These Analysts Think So

Is $160 The Level To Watch At Receptos? Wedbush Thinks So

Is $160 The Level To Watch At Receptos? Wedbush Thinks So

XOMA Corp Volatile Amid Differing Analyst Reports

XOMA Corp Volatile Amid Differing Analyst Reports

Wedbush Securities Reacts To Regulus Therapeutics Inc Announcing ATHENA Natural History Study

Wedbush Securities Reacts To Regulus Therapeutics Inc Announcing ATHENA Natural History Study

Analysts Weigh In: Regado Future 'Unclear' As Shares Fall Below Cash Value

Analysts Weigh In: Regado Future 'Unclear' As Shares Fall Below Cash Value

UPDATE: Wedbush Initiates Coverage on Relypsa on Potential Breakthrough Treatment for Hyperkalemia

UPDATE: Wedbush Initiates Coverage on Relypsa on Potential Breakthrough Treatment for Hyperkalemia

Wedbush Reiterates Outperform Rating on Omeros on Potential Increased OMS302 Use

Wedbush Reiterates Outperform Rating on Omeros on Potential Increased OMS302 Use

UPDATE: Wedbush Raises PT on Intercept Pharmaceuticals Following In-Line Q2 Financials

UPDATE: Wedbush Raises PT on Intercept Pharmaceuticals Following In-Line Q2 Financials

UPDATE: Wedbush Initiates Receptos at Outperform on Multiple Positive Factors

UPDATE: Wedbush Initiates Receptos at Outperform on Multiple Positive Factors